I-131 for thyroid cancer diagnosis and treatment can be considered “old era” theranostics.1Ga-68 prostate-specific membrane antigen (PSMA) and Lu-177 PSMA can be considered “new era” theranostic.2The new era of theranostics has revolutionized nuclear medicine through the prospective phase 3 clinical trials, which have resulted in its adoption into the treatment paradigms of patients, particularly those with neuroendocrine tumors and prostate cancer. This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.